AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2013
May 30, 2013
33422_dirs_2013-05-30_cf7b7144-fff8-45e5-bf84-3cc5ffe80083.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2013-05-28
Reporting Person: FREEMAN KEVIN D (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-05-28 | Common Stock | P | 1000 | $4.2115 | Acquired | 6500 | Direct |
Footnotes
F1: Reflects weighted average price. Range of prices were between $4.18 and $4.255. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21